Biliary cancer metastatic – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Thu, 18 Jun 2026 04:07:34 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Biliary cancer metastatic – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study Comparing Ivonescimab to FOLFOX Drug Combination for Patients with Advanced Biliary Tract Cancer https://clinicaltrials.eu/trial/study-comparing-ivonescimab-to-folfox-drug-combination-for-patients-with-advanced-biliary-tract-cancer/ Wed, 29 Apr 2026 15:02:42 +0000 https://clinicaltrials.eu/trial/study-comparing-ivonescimab-to-folfox-drug-combination-for-patients-with-advanced-biliary-tract-cancer/ This clinical trial is focused on studying a type of cancer known as advanced biliary tract cancer, which affects the bile ducts and gallbladder. The trial is comparing a new treatment called ivonescimab, also known by its code name AK112 / SMT112, with a standard chemotherapy regimen called FOLFOX. FOLFOX is a combination of three drugs: oxaliplatin, fluorouracil, and calcium folinate. The purpose of the study is to determine if ivonescimab is more effective than FOLFOX in treating this type of cancer.

Participants in the study will receive either ivonescimab or FOLFOX as a second-line treatment, which means it is given after the first treatment has not been successful. Ivonescimab is a special type of medication called a PD-1/VEGF bispecific antibody, which is designed to help the immune system fight cancer and block the growth of new blood vessels that tumors need to grow. The study will monitor how long patients live without their cancer getting worse, which is known as progression-free survival.

The trial will also look at other important outcomes, such as overall survival, which measures how long patients live after starting the treatment, and the disease control rate, which checks how well the cancer is managed with the treatment. Additionally, the study will assess the quality of life of participants using specific questionnaires. The trial is expected to run until 2030, with recruitment starting in 2025. Participants will be closely monitored throughout the study to ensure their safety and to gather information on the effectiveness of the treatments.

]]> Study of AMG 193 alone and combined with docetaxel for treatment of advanced MTAP-null solid tumors in adult patients https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-amg-193-alone-and-with-docetaxel-for-adults-with-advanced-mtap-null-solid-tumors/ Wed, 29 Apr 2026 15:00:20 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-amg-193-alone-and-with-docetaxel-for-adults-with-advanced-mtap-null-solid-tumors/ This study focuses on advanced MTAP-null solid tumors, which are cancers characterized by the absence of a specific gene called MTAP. The research evaluates a new medication called AMG 193, which will be tested both alone and in combination with another cancer drug called docetaxel. AMG 193 is taken as an oral tablet and belongs to a class of drugs known as PRMT5 inhibitors, which work by blocking certain proteins involved in cancer growth.

The purpose of this research is to understand how safe and effective AMG 193 is when used to treat patients with advanced solid tumors that lack the MTAP gene. The study is divided into multiple parts, with initial phases focusing on finding the right dose and checking how the body processes the medication, while later phases examine how well the treatment works in fighting the cancer.

During the study, participants will receive either AMG 193 alone or in combination with docetaxel. The treatment involves taking tablets by mouth. Throughout the study, doctors will monitor various aspects of the participants’ health and how their cancer responds to the treatment. They will track important measures such as tumor size changes and how long patients live without their disease getting worse.

]]> Study on Rilvegostomig and Chemotherapy for Patients with Biliary Tract Cancer After Surgery https://clinicaltrials.eu/trial/study-on-rilvegostomig-and-chemotherapy-for-patients-with-biliary-tract-cancer-after-surgery/ Wed, 29 Apr 2026 14:29:43 +0000 https://clinicaltrials.eu/trial/study-on-rilvegostomig-and-chemotherapy-for-patients-with-biliary-tract-cancer-after-surgery/ This clinical trial is focused on studying the effects of a new treatment for biliary tract cancer, which includes types like intrahepatic or extrahepatic cholangiocarcinoma and muscle invasive gallbladder cancer. The treatment being tested is called rilvegostomig, also known by its code name AZD2936. It is a type of protein treatment given through an infusion, which means it is delivered directly into the bloodstream. The study will also involve the use of various chemotherapy drugs, including gemcitabine, capecitabine, cisplatin, and tegafur, which are commonly used to treat cancer. These drugs will be given either by infusion or orally, depending on the specific medication.

The purpose of this study is to determine if rilvegostomig, when combined with chemotherapy, is safe and effective in delaying the return of cancer after surgery. Participants in the study will be randomly assigned to receive either the new treatment combination or a placebo with chemotherapy. The study will be conducted in a double-blind manner, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo. This helps ensure the results are unbiased. The study will take place over several months, with regular check-ups and assessments to monitor the participants’ health and the progression of the disease.

Throughout the study, the main focus will be on measuring how long participants remain free from cancer recurrence, known as recurrence-free survival. Other important aspects being evaluated include overall survival, which is the length of time participants live after treatment, and how well participants tolerate the treatment. The study aims to provide valuable information on whether rilvegostomig can be a beneficial addition to the current treatment options for biliary tract cancer.

]]> Study of DS-3939a for Patients with Advanced or Metastatic Solid Tumors https://clinicaltrials.eu/trial/study-of-ds-3939a-for-patients-with-advanced-or-metastatic-solid-tumors/ Wed, 29 Apr 2026 14:23:10 +0000 https://clinicaltrials.eu/trial/study-of-ds-3939a-for-patients-with-advanced-or-metastatic-solid-tumors/ This clinical trial is focused on studying advanced solid tumors, which are types of cancer that have spread beyond their original location and are difficult to treat. The trial will test a new treatment called DS-3939a, which is given as a solution through an intravenous infusion, meaning it is delivered directly into the bloodstream through a vein. The purpose of the study is to evaluate the safety and tolerability of DS-3939a and to see how well it works in treating these advanced cancers.

The study is divided into two parts. In the first part, participants will receive DS-3939a to assess its safety and how well it is tolerated by the body. In the second part, the study will continue to evaluate safety and also measure the treatment’s effectiveness at a recommended dose. This will involve looking at how the cancer responds to the treatment, which is known as the objective response rate. Participants may have different types of advanced cancers, including those of the lung, breast, ovary, and pancreas, among others.

Throughout the study, participants will be closely monitored for any side effects or changes in their health. This includes regular check-ups, laboratory tests, and imaging studies to track the progress of the treatment. The study aims to gather important information that could lead to new treatment options for people with advanced solid tumors. Some participants may receive a placebo, which is a substance with no active medication, to help compare the effects of DS-3939a.

]]>